CRISPR gene therapy is enhancing t-cell immnotherapy treatment of cancer and treatments in people could be available within 2 to 3 years
Marcela V. Maus, M.D., Ph.D., of Harvard Medical School identified three important improvements that CRISPR gene editing could potentially bring to T-cell-based therapies. 1. being more-effective tumor responses. 2. the targeted nature of CRISPR-mediated CAR integration into the genome might “prove safer than random integration, which carries the potential risk of generating a harmful mutation,” …